Gene Loss May Signal PARP Inhibitor Response
Early lab work suggests ESCO2 status could one day help show which cancers respond to these drugs.
Updated on Nov. 6, 2026 in Cancer

Researchers at NYU Langone Health's Perlmutter Cancer Center report in Nature Cell Biology that loss of the gene ESCO2 makes cancer cells more sensitive to PARP inhibitors, a class of cancer drugs. The work is laboratory research, so its relevance to patients has not yet been established.
Why it matters
PARP inhibitors are already used in some cancers, but not every patient responds, so markers that predict sensitivity could eventually help clinicians choose treatment more carefully. The finding points to a possible biological signal that could guide future decisions, though it has not yet been tested in patients.
This is a preclinical study that used CRISPR screens in breast and small cell lung cancer models and tested partial ESCO2 loss across colorectal, ovarian, and lung cancer cells. The findings come from cell models rather than human participants, so they are preliminary.
The players
NYU Langone Health's Perlmutter Cancer Center
A cancer center within NYU Langone Health that conducts laboratory and clinical cancer research across many tumor types.
Eli Rothenberg
A co-corresponding author of the study, working in cancer biology on DNA replication and repair.
Dipika Gupta
A co-corresponding author of the study, contributing to research on DNA damage responses in cancer.
The details
PARP inhibitors work partly by blocking a repair pathway cells use to fix damaged DNA. In this study, cells with reduced ESCO2 retained their homologous recombination repair response, but reducing ESCO2 increased G-quadruplexes, unusual DNA structures, at a small set of replication sites concentrated in repetitive regions near the centromere. When PARP inhibition was added, these structures built up further, DNA synthesis declined, and damage increased near centromeres. The protective response depended on PARP1 activity and involved the proteins TIMELESS and DDX11.
Timeline
Article about the Nature Cell Biology study published November 6, 2026.
Health Landscape
PARP inhibitors are an established class of targeted cancer drugs, but response varies widely among patients and tumor types. Identifying biological markers such as ESCO2 status could help match these drugs to the tumors most likely to respond.
If you are living with cancer and wondering whether a PARP inhibitor is appropriate, that is a conversation to have with your oncologist, who can review whether current biomarker testing applies to your situation. This study does not change current treatment guidance.
The takeaway
Lab research like this helps explain why some tumors respond to PARP inhibitors and others do not, which may eventually support more precise treatment choices. Patients should continue to rely on their oncology team for decisions, and ask whether biomarker testing is available.
Further reading
For broader context on how these treatments are studied, explore Cancer research coverage.
Source note: This article includes information reported by GEN - Genetic Engineering and Biotechnology News.





